Understand the source comparison
Peptide Protocol Comparison: Mechanism, Dosing, and Telomerase Pathway
MK 677 Ghrelin receptor agonist → GH/IGF-1 elevation 12.5–25mg once daily Oral (capsule) or sublingual IGF-1 → PI3K/AKT → hTERT transcription N/A (oral formulation stable at room temp) Epithalon Direct chromatin interaction near telomeric regions (proposed) 5–
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- MK 677
- Ghrelin receptor agonist → GH/IGF-1 elevation
- 12.5–25mg once daily
- Oral (capsule) or sublingual
- IGF-1 → PI3K/AKT → hTERT transcription
- N/A (oral formulation stable at room temp)
- Epithalon
- Direct chromatin interaction near telomeric regions (proposed)
- 5–10mg daily for 10 days, cycled every 3–6 months
- Subcutaneous injection
- Direct telomerase activation in fibroblasts and lymphocytes
- 2–8°C, use within 28 days
- GHRP-2
- Hypothalamic GH secretagogue
- 100–300mcg 2–3× daily
- Pulsatile GH → IGF-1 → hTERT upregulation
- Thymalin
- Thymic peptide bioregulator → immune restoration
- 10mg daily for 10 days, cycled 2× annually
- Intramuscular injection
- Restores T-cell telomerase activity via thymic function
- GHRP-6
- GH-releasing hexapeptide
- 100–200mcg 2–3× daily
- Similar to GHRP-2, slightly lower potency